Neuromuscular transmission: New concepts and agents

Journal of Critical Care

Volumn 24, Issue 1, 2009, Pages 36-42

  de Boer, Hans D ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

Author keywords

Cholinesterase inhibitor; Neuromuscular block; Suggamadex

Indexed keywords

ATROPINE; CHOLINESTERASE INHIBITOR; DESFLURANE; EDROPHONIUM; GLYCOPYRRONIUM BROMIDE; MOXIFLOXACIN; NEOSTIGMINE; PLACEBO; PROPOFOL; REMIFENTANIL; ROCURONIUM; SEVOFLURANE; SUGAMMADEX; SUXAMETHONIUM; VECURONIUM;

BRONCHOSPASM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HEART DISEASE; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; LUNG DISEASE; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR TRANSMISSION; REVIEW; SINGLE DRUG DOSE;

ANDROSTANOLS; ANESTHESIA RECOVERY PERIOD; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; GAMMA-CYCLODEXTRINS; HUMANS; METABOLIC CLEARANCE RATE; MONITORING, INTRAOPERATIVE; MUSCARINIC ANTAGONISTS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR NONDEPOLARIZING AGENTS; PATIENT SELECTION; SAFETY; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME; VECURONIUM BROMIDE;

EID: 61449175653     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrc.2008.08.004     Document Type: Review

References (26)

1. Mencke T., Echternach M., Kleinschmidt S., et al. Laryngeal morbidity and quality of tracheal intubation: a randomized controlled trial. Anesthesiology 98 (2003) 1049-1056
2. Arbous M.S., Meursing A.E.E., van Kleef J.W., et al. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology 102 (2005) 257-268
3. Viby-Mogensen J., Jørgensen B.C., and Ørding H. Residual curarization in the recovery room. Anesthesiology 50 (1979) 539-541
4. Debaene B., Plaud B., Dilly M.P., et al. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 98 (2003) 1042-10485
5. Berg H., Roed J., Viby-Mogensen J., et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomized, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 41 (1997) 1095-1103
6. Gijsenbergh F., Ramael S., Houwing N., et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 103 (2005) 695-703
7. Shields M., Mirakhur R.K., Moppett I., et al. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 96 (2006) 36-43
8. Sorgenfrei I.F., Norrild K., Larsen P.B., et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 104 (2006) 667-674
9. Khunl-Brady K., Rex C., Kjaer C.C., et al. Reversal of high dose rocuronium with Org 25969. Eur J Anaesthesiol 22 suppl S34 (2005) 121
10. Vanacker B., Vermeyen K., Struys M.R.F., et al. Reversal by Org 25969 is not affected by sevoflurane when compared with propofol. Anesth Analg 104 (2007) 563-568
11. de Boer H.D., Driessen J.J., Marcus M.A., et al. Reversal of rocuronium-induced (1.2 mg/kg) neuromuscular block by Org 25969: a multi-center dose finding and safety study. Anesthesiology 107 (2007) 239-244
12. Suy K., Morias K., Hans P., et al. Fast, effective and safe reversal of rocuronium and vecuronium-induced moderate neuromuscular block by the selective relaxant binding agent Org 25969. Anesthesiology 106 (2007) 283-288
13. Rex C., Khunl-Brady K., Sielenkaemper A., et al. Reversal of high dose rocuronium (1.2 mg/kg) with Org 25969. Anesthesiology 103 (2005) A1129
14. Sacan O., Klein K., and White P.F. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg 104 (2007) 569-574
15. Lee C., Jahr J.S., Candiotti K., et al. Reversal of profound rocuronium neuromuscular block with sugammadex is faster than recovery from succinylcholine. Anesthesiology 107 (2007) A988
16. De Kam P., van Kuijk J., Smeets J., et al. Single sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology 107 (2007) A1580
17. Staals L.M., Snoeck M.M.J., Flocton E.A., et al. The efficacy of sugammadex in patients with impaired versus normal renal failure. Eur J Anesthesiol 24 suppl 39 (2007) 122
18. Amao R., Zornow M.H., McTaggart Cowan R., et al. Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease. Anesthesiology 107 (2007) A1582
19. Dahl V., Pendeville P.E., Hollman M.W., et al. Reversal of rocuronium-induced neuromuscular blockade by sugammadex in cardiac patients. Anesthesiology 107 (2007) A1581
20. Plaud B., Meretoja B., Mirakhur R.K., et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in paediatric and adult patients. Eur J Anesthesiol 24 suppl 39 (2007) 124
21. McDonagh D.L., Benedict P.E., Kovac A.L., et al. Efficacy and safety of sugammadex for reversal of rocuronium-induced blockade in elderly patients. Anesthesiology 107 (2007) A1583
22. Sparr H.J., Vermeyen K.M., Beaufort A.M., et al. Anesthesiology 106 (2007) 935-943
23. Bom A., Bradley M., Cameron K., et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 41 (2002) 266-270
24. Proost J.H., Eriksson L.I., Mirakhur R.K., et al. Urinary, biliary and faecal excretion of rocuronium in humans. Br J Anaesth 85 (2000) 717-723
25. van den Broek L., Wierda J.M.K.H., Smeulers N.J., et al. Clinical pharmacology of rocuronium (ORG 9426): Study of the time course of action, dose requirement, reversibility and pharmacokinetics. J Clin Anesth 6 (1994) 288-296
26. de Boer H.D., Driessen J.J., van Egmond J., et al. Non-steroidal neuromuscular blocking agents to re-establish paralysis after reversal of rocuronium-induced neuromuscular block with sugammadex. Can J Anaesth 55 (2008) 124-125